Prostate cancer is the second most commonly diagnosed type of cancer in men. The average age at diagnosis is about 66 years.

     More than 80% of men will develop prostate cancer after age 80. In 2013, in the EU-28 the standardized average death rate for prostate cancer was 39.4 per 100,000 men. However, in most cases, it will be slow growing. With about 307,000 deaths, prostate cancer is the fifth leading cause of cancer death in men (6.6% of all male deaths).

One of the first anti-cancer vaccines was created against prostate cancer and is called Provenge. After several years of administration, due to unreliable results, the vaccine was stopped. This provoked strong reactions from the country. Now the vaccine can be found in different parts of value associations 93,000 dollars for a patient. 

Currently, treatment for prostate cancer is done with hormone therapy and can control the cancer for a long period of time by reducing tumor size and thus reducing pain and other symptoms.

Unfortunately, in our country, prostate cancer is most often detected in the manifestations of bone metastases, i.e. in the 4th stage.

This problem, together with the rapid development of resistance to hormonal preparations (an average of 5 years), further complicates treatment, and the 45.7% over 5-year survival rate in our patients is a good treatment indicator for this very common and severe disease. 

 Over the past 20 years, five-year survival for all stages has generally increased. According to the latest data, the ten-year survival rate is 93%, and the fifteen-year-old is 77%.

The dramatic improvement in survival is due in part to earlier diagnosis, but also to some improvements in treatment. 

 Cancers of the male reproductive system mainly involve Ca prostatae and Ca testis. The number of patients tracked by us in February 2022. is 35. 3/4 of them have prostate carcinoma and the rest have testicular carcinoma.